Overview Dividends

(ISRG) Intuitive Surgical - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46120E6023

Robotic, Surgical, System, Instruments, Diagnostic

ISRG EPS (Earnings per Share)

EPS Growth (3Y CAGR): 27.52%
EPS Trend (3Y Correlation): 95.5%

ISRG Revenue

Revenue Growth (3Y CAGR): 16.27%
Revenue Trend (3Y Correlation): 96.9%

Risk via 10d forecast
Volatility	32.2%
Value at Risk 5%th	46.8%
Relative Tail Risk	-11.78%

Reward TTM
Sharpe Ratio	0.12
Alpha	-13.84

Character TTM
Hurst Exponent	0.459
Beta	1.227
Beta Downside	1.254

Drawdowns 3y
Max DD	29.63%
Mean DD	8.75%
Median DD	6.08%

Description: ISRG Intuitive Surgical September 24, 2025

Intuitive Surgical (NASDAQ: ISRG) designs, manufactures, and markets robotic and endoluminal platforms that enable minimally invasive procedures. Its flagship da Vinci Surgical System delivers multi-port robotic assistance for a broad range of operations, while the newer Ion endoluminal system expands the portfolio into bronchoscopic lung biopsies, positioning the firm across both therapeutic and diagnostic spaces.

In FY 2023 the company generated approximately $5.6 billion in revenue, with the da Vinci system accounting for roughly 85 % of sales and the Ion platform contributing a rapidly growing share as hospitals adopt minimally invasive diagnostics. Operating margins have hovered near 30 % due to high-margin consumables (staplers, energy instruments) and recurring service contracts that provide a stable cash-flow base. The firm’s direct-sales model-comprising capital and clinical teams-supports high adoption rates, but also concentrates revenue exposure to hospital capital-budget cycles.

Key economic drivers include rising global healthcare spending, an aging population that increases demand for less invasive surgeries, and a projected 10 % CAGR for the worldwide robotic surgery market through 2028. A sector-specific risk is the potential for competitive entry from emerging robotic platforms, which could compress pricing or shift market share if they achieve comparable clinical outcomes.

For a deeper, data-driven assessment of ISRG’s valuation and risk profile, the ValueRay platform offers a granular, model-backed view worth exploring.

ISRG Stock Overview

Market Cap in USD	204,261m
Sub-Industry	Health Care Equipment
IPO / Inception	2000-06-13
Return 12m vs S&P 500	-10.9%
Analyst Rating	4.03 of 5

ISRG Dividends

Currently no dividends paid

ISRG Growth Ratios

CAGR 3y	28.28%
CAGR/Max DD Calmar Ratio	0.95
CAGR/Mean DD Pain Ratio	3.23
Current Volume	1880.3k
Average Volume	2116.7k

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (2.75b TTM) > 0 and > 6% of Revenue (6% = 576.7m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 8.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 69.93% (prev 70.41%; Δ -0.47pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 2.96b > Net Income 2.75b (YES >=105%, WARN >=100%)

Net Debt (-2.81b) to EBITDA (3.58b) ratio: -0.78 <= 3.0 (WARN <= 3.5)

Current Ratio 4.73 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (361.8m) change vs 12m ago -0.25% (target <= -2.0% for YES)

Gross Margin 66.41% (prev 66.98%; Δ -0.57pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 51.82% (prev 44.34%; Δ 7.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 33.19 (EBITDA TTM 3.58b / Interest Expense TTM 90.4m) >= 6 (WARN >= 3)

Altman Z'' 7.38

(A) 0.35 = (Total Current Assets 8.53b - Total Current Liabilities 1.80b) / Total Assets 19.35b

(B) 0.33 = Retained Earnings (Balance) 6.42b / Total Assets 19.35b

(D) 2.79 = Book Value of Equity 6.45b / Total Liabilities 2.31b

Total Rating: 7.38 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 81.91

1. Piotroski 7.0pt = 2.0

2. FCF Yield 1.14% = 0.57

3. FCF Margin 23.63% = 5.91

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -0.78 = 2.50

6. ROIC - WACC (= 4.04)% = 5.04

7. RoE 16.08% = 1.34

8. Rev. Trend 96.90% = 7.27

9. EPS Trend 95.55% = 4.78

What is the price of ISRG shares?

As of November 15, 2025, the stock is trading at USD 549.51 with a total of 1,880,253 shares traded.
Over the past week, the price has changed by -1.87%, over one month by +25.92%, over three months by +15.18% and over the past year by +2.18%.

Is Intuitive Surgical a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Intuitive Surgical (NASDAQ:ISRG) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 81.91 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ISRG is around 564.06 USD . This means that ISRG is currently overvalued and has a potential downside of 2.65%.

Is ISRG a buy, sell or hold?

Intuitive Surgical has received a consensus analysts rating of 4.03. Therefore, it is recommended to buy ISRG.

Strong Buy: 14
Buy: 8
Hold: 10
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the ISRG price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	593	7.9%
Analysts Target Price	593	7.9%
ValueRay Target Price	640.4	16.5%

ISRG Fundamental Data Overview November 11, 2025

Market Cap USD = 204.26b (204.26b USD * 1.0 USD.USD)
P/E Trailing = 76.3179
P/E Forward = 60.241
P/S = 21.2506
P/B = 12.0652
P/EG = 3.572
Beta = 1.692
Revenue TTM = 9.61b USD
EBIT TTM = 3.00b USD
EBITDA TTM = 3.58b USD
Long Term Debt = unknown (none)
Short Term Debt = 33.5m USD (from shortTermDebt, last fiscal year)
Debt = 146.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -2.81b USD (from netDebt column, last quarter)
Enterprise Value = 199.50b USD (204.26b + Debt 146.0m - CCE 4.91b)
Interest Coverage Ratio = 33.19 (Ebit TTM 3.00b / Interest Expense TTM 90.4m)
FCF Yield = 1.14% (FCF TTM 2.27b / Enterprise Value 199.50b)
FCF Margin = 23.63% (FCF TTM 2.27b / Revenue TTM 9.61b)
Net Margin = 28.58% (Net Income TTM 2.75b / Revenue TTM 9.61b)
Gross Margin = 66.41% ((Revenue TTM 9.61b - Cost of Revenue TTM 3.23b) / Revenue TTM)
Gross Margin QoQ = 66.36% (prev 66.44%)
Tobins Q-Ratio = 10.31 (Enterprise Value 199.50b / Total Assets 19.35b)
Interest Expense / Debt = 61.92% (Interest Expense 90.4m / Debt 146.0m)
Taxrate = 17.07% (146.0m / 855.2m)
NOPAT = 2.49b (EBIT 3.00b * (1 - 17.07%))
Current Ratio = 4.73 (Total Current Assets 8.53b / Total Current Liabilities 1.80b)
Debt / Equity = 0.01 (Debt 146.0m / totalStockholderEquity, last quarter 16.93b)
Debt / EBITDA = -0.78 (Net Debt -2.81b / EBITDA 3.58b)
Debt / FCF = -1.24 (Net Debt -2.81b / FCF TTM 2.27b)
Total Stockholder Equity = 17.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.19% (Net Income 2.75b / Total Assets 19.35b)
RoE = 16.08% (Net Income TTM 2.75b / Total Stockholder Equity 17.08b)
RoCE = 17.10% (EBIT 3.00b / Capital Employed (Total Assets 19.35b - Current Liab 1.80b))
RoIC = 14.57% (NOPAT 2.49b / Invested Capital 17.08b)
WACC = 10.53% (E(204.26b)/V(204.41b) * Re(10.54%) + (debt cost/tax rate unavailable))
Discount Rate = 10.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.50%
[DCF Debug] Terminal Value 67.02% ; FCFE base≈1.60b ; Y1≈1.40b ; Y5≈1.13b
Fair Price DCF = 39.51 (DCF Value 14.01b / Shares Outstanding 354.5m; 5y FCF grow -15.34% → 3.0% )
EPS Correlation: 95.55 | EPS CAGR: 27.52% | SUE: 3.30 | # QB: 2
Revenue Correlation: 96.90 | Revenue CAGR: 16.27% | SUE: 1.55 | # QB: 5

Additional Sources for ISRG Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle